Skip to main content

Rafael Simó Canonge

Institutions of which they are part

Head of group
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Rafael Simó Canonge

Institutions of which they are part

Head of group
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Projects

Premi a la trajectòria investigadora als Hospitals de l'ICS

IP: Rafael Simó Canonge
Collaborators: -
Funding agency: Institut Català de la Salut
Funding: 5000
Reference: ICS/TRAJECTORIA.HOSP/2021/SIMÓ
Duration: 28/06/2021 - 28/06/2021

Beques de Formació de Personal Investigador (FPI) Identificación de los mediadores comunes a la neurodegeneracion inducida por la diabetes en retina y cerebro / Unraveling the common mediators of retinal and brain diabetes-induced neurodegeneration (U

IP: Rafael Simó Canonge
Collaborators: Beques de Formació de Personal Investigador (FPI) Identificación de los mediadores comunes a la neurodegeneracion inducida po, Miriam Izquierdo Sans
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 98960
Reference: PRE2020-095747
Duration: 01/09/2021 - 30/08/2025

Ministerio de Ciencia

Estudio de seguridad y eficacia de la sitagliptina en colirio para el tratamiento de los estadios iniciales de retinopatía diabética.

IP: Rafael Simó Canonge
Collaborators: Marc Rivas Agudo, Cristina Hernández Pascual, José García Arumí
Funding agency: Instituto de Salud Carlos III
Funding: 573650
Reference: ICI20/00129
Duration: 01/01/2021 - 31/10/2026

H2O Health Outcomes Observatory

IP: Yolima Cossio Gil
Collaborators: Cristina Hernández Pascual, Natalia Borruel Sainz, Gemma Galán Martinez, Monica Sanchez Bartres, Marta Ferri Peradalta, Rafael Simó Canonge, Joan Carles Peiró Ruiz
Funding agency: The Innovative Medicines Initiative
Funding: 1097257.5
Reference: H2O_IMI2-2020
Duration: 01/10/2020 - 30/09/2025

Related news

The work represents a paradigm shift in the clinical approach to this chronic, multifactorial disease, based on the clinical context of each patient and not only on weight loss.

The results of a phase 3 clinical trial show that orforglipron reduces body weight by an average of 11% and improves cardiovascular risk factors.

Dr. Maria Llorián-Salvador, from the Diabetes and Metabolism Research Group at VHIR, is leading this project to identify new therapies for this inherited disease that causes progressive vision loss.

Related professionals

José Luis Peiró Ibáñez

José Luis Peiró Ibáñez

Bioengineering, Cell Therapy and Surgery in Congenital Malformations
Read more
Héctor Carmona Díez

Héctor Carmona Díez

Research assistant
Clinical Pharmacology
Read more
Laura Costa Comellas

Laura Costa Comellas

Predoctoral researcher
Pediatric Neurology
Read more
Javier Sánchez López

Javier Sánchez López

Research technician
Research Group on Status Epilepticus and Acute Seizures
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.